Annual Cash & Cash Equivalents
$86.89 M
+$48.64 M+127.16%
December 31, 2023
Summary
- As of February 8, 2025, JSPR annual cash & cash equivalents is $86.89 million, with the most recent change of +$48.64 million (+127.16%) on December 31, 2023.
- During the last 3 years, JSPR annual cash & cash equivalents has risen by +$67.05 million (+337.98%).
- JSPR annual cash & cash equivalents is now at all-time high.
Performance
JSPR Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$92.50 M
-$14.32 M-13.40%
September 30, 2024
Summary
- As of February 8, 2025, JSPR quarterly cash and cash equivalents is $92.50 million, with the most recent change of -$14.32 million (-13.40%) on September 30, 2024.
- Over the past year, JSPR quarterly cash and cash equivalents has dropped by -$11.37 million (-10.94%).
- JSPR quarterly cash and cash equivalents is now -28.51% below its all-time high of $129.40 million, reached on March 31, 2023.
Performance
JSPR Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
JSPR Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +127.2% | -10.9% |
| 3 y3 years | +338.0% | -10.9% |
| 5 y5 years | +338.0% | -10.9% |
JSPR Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +127.2% | -28.5% | +141.8% |
| 5 y | 5-year | at high | +338.0% | -28.5% | +366.3% |
| alltime | all time | at high | +338.0% | -28.5% | +366.3% |
Jasper Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $92.50 M(-13.4%) |
| Jun 2024 | - | $106.82 M(-9.8%) |
| Mar 2024 | - | $118.47 M(+36.4%) |
| Dec 2023 | $86.89 M(+127.2%) | $86.89 M(-16.3%) |
| Sep 2023 | - | $103.87 M(-10.3%) |
| Jun 2023 | - | $115.81 M(-10.5%) |
| Mar 2023 | - | $129.40 M(+238.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2022 | $38.25 M(-54.8%) | $38.25 M(-24.9%) |
| Sep 2022 | - | $50.95 M(-16.2%) |
| Jun 2022 | - | $60.81 M(-13.6%) |
| Mar 2022 | - | $70.40 M(-16.9%) |
| Dec 2021 | $84.70 M(+327.0%) | $84.70 M(-16.1%) |
| Sep 2021 | - | $100.91 M(+408.6%) |
| Dec 2020 | $19.84 M | $19.84 M |
FAQ
- What is Jasper Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Jasper Therapeutics?
- What is Jasper Therapeutics annual cash & cash equivalents year-on-year change?
- What is Jasper Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Jasper Therapeutics?
- What is Jasper Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Jasper Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of JSPR is $86.89 M
What is the all time high annual cash & cash equivalents for Jasper Therapeutics?
Jasper Therapeutics all-time high annual cash & cash equivalents is $86.89 M
What is Jasper Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, JSPR annual cash & cash equivalents has changed by +$48.64 M (+127.16%)
What is Jasper Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of JSPR is $92.50 M
What is the all time high quarterly cash and cash equivalents for Jasper Therapeutics?
Jasper Therapeutics all-time high quarterly cash and cash equivalents is $129.40 M
What is Jasper Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, JSPR quarterly cash and cash equivalents has changed by -$11.37 M (-10.94%)